drugset / Trial / NCT05243251

Olanzapine Anorexia Cachexia

NCT05243251

Phase 3 Completed 164 enrolled Cairo University
RandomizedParallel-groupDouble-blindSupportive care

Summary

164 patients will be recruited..Adult patients diagnosed with incurable solid tumors and CCAA who presented to Kasr Al-Ainy Center of Clinical Oncology and Nuclear Medicine (NEMROCK) - Kasr Al-Ainy School of Medicine - Cairo University will be randomly distributed into 1:1..82 will receive Olanzapine 5 mg daily at night and 82 patients will receive placebo for 4 weeks. Primary outcome is Change in loss of appetite score from day 0 to day 7 of treatment and secondary outcomes change in body weight, change in loss of appetite score..and change in quality of life

Timeline

Start
2021-12-25
Primary completion
2022-11-21
Completion
2022-12-14

Drugs

EvaluationDrugModalityDoseRoute
Comparator Olanzapine Small molecule 5 mg Oral

Indications